Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Carbohydr Polym ; 301(Pt B): 120347, 2023 Feb 01.
Article in English | MEDLINE | ID: mdl-36446486

ABSTRACT

Sulfobutylether ß-cyclodextrin (SBE-ß-CD) is a polyanionic cyclic oligosaccharide that contains glucopyranose units forming a torus ring-like structure. SBE-ß-CD is gifted with many favorable properties viz. relatively high solubility (>50 folds compared to ß-CD), improved stability, and biocompatibility that praised SBE-ß-CD as a smart polymer for drug delivery applications. Commercially, SBE-ß-CD is popular by its brand name Captisol®. The present review discusses the structure, properties, and preparation methods of SBE-ß-CD-based inclusion complexes (ICs). Furthermore, we discuss here the preparation and applications of SBE-ß-CD ICs-based nanoparticulate drug delivery systems, which combines the merits of both, ICs (enhanced solubility) and nanoparticles (NPs, targeted therapy). Patents on and FDA-approved Captisol®-enabled products are tabulated in the benefit of readers. The toxicological aspects and current clinical status of SBE-ß-CD or SBE-ß-CD-based products are briefly explained in the present review. In our opinion, the present review would be a pathfinder to allow dissemination of information on SBE-ß-CD.


Subject(s)
Stimuli Responsive Polymers , beta-Cyclodextrins , Biopolymers , Drug Delivery Systems
2.
Article in English | MEDLINE | ID: mdl-32723263

ABSTRACT

The article has been withdrawn by the Editorial office of the journal Anti-Cancer Agents in Medicinal Chemistry because of the lack of clarity and obscurity in the content regarding language. Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policiesmain.php Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

3.
Int J Biol Macromol ; 104(Pt A): 799-812, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28648637

ABSTRACT

The near future of drug delivery system would lie in the search of a versatile and innocuous material, based mostly on the natural resources. The tamarind seed xyloglucan (XG) is a natural neutral hemicellulose and a hydrophilic polysaccharide consisting of a main chain of glucan backbone with xylose and galactose side chains. XG is endowed with idiosyncratic mucoadhesive and in situ gelling properties which rated XG as an attractive, functional polymer for numerous drug delivery applications. In milieu of this, the present review is designed to underline the plausible potential of XG or XG-based systems in drug delivery. The feasibility of surface-tailoring, the flexibility of chemical-modification, and the possibility as ligand-conjugations grant XG an extraordinary consideration in the scientific territory. The authors are hopeful that the versatility of XG would meet the expectations of regulatory authorities and the XG-based products will serve the therapeutic needs of the community in the future, if sufficiently investigated and promising outcomes are obtained in human subjects.


Subject(s)
Drug Carriers , Glucans , Xylans , Chemical Phenomena , Drug Carriers/chemical synthesis , Drug Carriers/chemistry , Drug Carriers/isolation & purification , Glucans/chemical synthesis , Glucans/chemistry , Glucans/isolation & purification , Humans , Xylans/chemical synthesis , Xylans/chemistry , Xylans/isolation & purification
4.
Carbohydr Polym ; 157: 875-902, 2017 Feb 10.
Article in English | MEDLINE | ID: mdl-27988003

ABSTRACT

N,N,N-trimethyl chitosan (TMC), a quaternized hydrophilic derivative of chitosan (CHT), outperformed the well-known solubility issues raised by CHT. The excellent properties offered by TMC provide it a significant edge for nanoparticle (NP) formation over other nanocarrier materials. Recently, TMC NPs have been applied to various fields like pharmaceutical, biomedical, biomaterials, and biotechnological field. The aim of this review is, therefore, to bring the TMC into the limelight so as to appraise it as an attractive functional polymer for nanomedicine applications which is facing oversight, at present, by regulatory agencies and manufacturers. The versatility of surface-tailoring, the capability of further chemical modifications, and the feasibility of ligand-conjugations in TMC polymer will further assist the scientists for reaching new dimensions in the nano-assembly of novel structures based on TMC.


Subject(s)
Chitosan/chemistry , Nanomedicine , Nanoparticles , Drug Carriers , Polymers
5.
Int J Biol Macromol ; 88: 476-90, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27017981

ABSTRACT

Although chitosan (CHT, a linear cationic polysaccharide) is biodegradable, biocompatible, non-toxic, and mucoadhesive in nature, the low solubility of CHT in aqueous and alkaline media limits its applicability in pharmaceutical and biomedical field. This necessitate the introduction of new chemically-modified derivatives of CHT those can surmount the solubility barrier. Herein, N,N,N-trimethyl chitosan (TMC), a quaternized hydrophilic derivative of CHT, was synthesized by two-step reductive methylation of CHT and characterized for (1)H NMR and zeta potential measurements. Polyelectrolyte complexes (PECs) based on TMC and dextran sulfate (DS) were prepared via ionic interactions between charged functional groups of former polysaccharides at different pH conditions (pH 5, 8, 10, and 12) and characterized for physicochemical (particle size and zeta potential) and solid- state characterizations (HR-TEM, SEM, FTIR, TGA and XRD). At alkaline pH conditions, the participant polymer chains (TMC and DS) are sufficiently close to form more stable PECs. The release efficiency was assessed after loading a model drug into optimized PEC formulation. Data indicated that the PECs fabricated at alkaline pH presents a reliable formulation for pharmaceutical and biomedical applications.


Subject(s)
Chitosan/chemistry , Dextran Sulfate/chemistry , Drug Compounding , Nanoparticles/chemistry , Administration, Intranasal , Chitosan/chemical synthesis , Chitosan/therapeutic use , Dextran Sulfate/therapeutic use , Humans , Hydrogen-Ion Concentration , Hydrophobic and Hydrophilic Interactions , Nanoparticles/therapeutic use , Particle Size , Solubility
6.
Artif Cells Nanomed Biotechnol ; 44(7): 1615-25, 2016 Nov.
Article in English | MEDLINE | ID: mdl-26757773

ABSTRACT

The polyelectrolyte complexes (PECs) are versatile formulations formed by electrostatic interactions between oppositely charged biopolymers. PECs have been investigated widely by the researchers to explore the virtues of this formulation viz. high biocompatibility, excellent biodegradability, low toxicity, cost-effective, environment-friendly, and energy-efficient production. The prime object of the present review is to present the prominent features of PECs including mechanism of PEC formation, structural models of PECs, interactions involved in PEC formation, steps involved in PEC fabrication, factors affecting the formation of PECs and applications of PECs. The patents pertaining to PECs have briefly been tabulated as well.


Subject(s)
Polyelectrolytes/chemistry , Static Electricity
7.
Expert Opin Drug Deliv ; 13(1): 85-92, 2016.
Article in English | MEDLINE | ID: mdl-26393289

ABSTRACT

INTRODUCTION: The brain-blood ratio is an important model correlating the brain-targeting ability of neurotherapeutics with the CNS pharmacokinetics, which need to be presented before the scientific community for exploration of its scientific worth. The purpose of this article is to bring this key concept and its precise discussion to the attention of the researchers. AREAS COVERED: Three major points are discussed herein: First, the significance of brain-blood ratio with respect to investigational neurotherapeutics, and carrier systems and correlation of its research findings with the brain targeting efficiency. Second, the various factors influencing the brain-blood ratio. Third, the various strategies for enhancing the brain-blood ratio. In addition, the benchmark criteria for CNS-likeness of drug molecules and the correlation of brain-blood ratio with brain targeting ability of neurotherapeutics have been tabulated. EXPERT OPINION: The brain-blood ratio (also referred to as the brain-plasma ratio) represents one of the tools available today for estimation of CNS pharmacokinetics. It is preferred over other complicated techniques (in situ brain perfusion and microdialysis) due to its ease of use and practicality. We are optimistic that the brain-blood ratio offers an excellent way of evaluating brain-targeting efficiency of neurotherapeutics effectively. In our opinion, it is a very fundamental aspect of brain bioavailability and needs to be presented in a precise way.


Subject(s)
Blood-Brain Barrier/metabolism , Central Nervous System Agents/administration & dosage , Central Nervous System Agents/pharmacokinetics , Drug Delivery Systems , Central Nervous System Agents/blood , Central Nervous System Agents/cerebrospinal fluid , Humans
8.
J Drug Target ; 23(9): 775-88, 2015.
Article in English | MEDLINE | ID: mdl-25758751

ABSTRACT

Nose to brain delivery of neurotherapeutics have been tried by several researchers to explore the virtues of this route viz. circumvention of BBB, avoidance of hepatic metabolism, practicality, safety, ease of administration and non-invasiveness. Nanoparticle (NP) therapeutics is an emerging modality for the treatment of Parkinson's disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy and/or bioavailability of neurotherapeutics. This review presents a concise incursion into the nanomedicines suitable for PD therapy delivered via naso-brain transport. Clinical signs of PD, its pathophysiology, specific genetic determinants, diagnosis and therapy involved have been hashed out. Properties of brain-targeting NPs, transport efficacy and various nanocarriers developed so far also been furnished. In our opinion, nanotechnology-enabled naso-brain drug delivery is an excellent means of delivering neurotherapeutics and is a promising avenue for researchers to develop new formulations for the effective management of PD.


Subject(s)
Antiparkinson Agents/administration & dosage , Antiparkinson Agents/pharmacokinetics , Brain/metabolism , Drug Delivery Systems/methods , Nanomedicine/methods , Nanoparticles/administration & dosage , Nasal Mucosa/metabolism , Parkinson Disease/drug therapy , Administration, Intranasal , Brain/drug effects , Humans , Models, Neurological , Parkinson Disease/metabolism
9.
J Drug Target ; 22(9): 769-89, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24964054

ABSTRACT

Topical therapy is at the forefront in treating nail ailments (especially onychomycosis and nail psoriasis) due to its local effects, which circumvents systemic adverse events, improves patient compliance and reduces treatment cost. However, the success of topical therapy has been hindered due to poor penetration of topical therapeutics across densely keratinized nail plate barrier. For effective topical therapy across nail plate, ungual drug permeation must be enhanced. Present review is designed to provide an insight into prime aspects of transungual drug delivery viz. nail structure and physiology, various onychopathies, techniques of nail permeation enhancement and in vitro models for trans-nail drug permeation studies. Updated list of drug molecules studied across the nail plate and key commercial products have been furnished with sufficient depth. Patents pertinent to, and current clinical status of transungual drug delivery have also been comprehensively reviewed. This is the first systematic critique encompassing the detailed aspects of transungual drug delivery. In our opinion, transungual drug delivery is a promising avenue for researchers to develop novel formulations, augmenting pharmaceutical industries to commercialize the products for nail disorders.


Subject(s)
Chemistry, Pharmaceutical/methods , Drug Delivery Systems/methods , Nail Diseases/drug therapy , Permeability , Administration, Topical , Animals , Cadaver , Humans , Models, Animal , Nails/anatomy & histology , Onychomycosis/drug therapy , Patents as Topic , Psoriasis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL